• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tretten (Coagulation Factor XIII A-Subunit [Recombinant])

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tretten (Coagulation Factor XIII A-Subunit [Recombinant])

  • Profile

Profile

Contact Information

Contact: Norvo Nordisk
Website: http://www.tretten.com/

Currently Enrolling Trials

    Show More

    General Information

    Tretten consists of coagulation factor XIII A-subunit (recombinant). Recombinant human Factor XIII (rFXIII) is integral in the formation of blood clots. In the absence of Factor XIII, loosely formed clots are developed, leading to bleeding complications.

    Tretten is specifically indicated for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII) A-subunit deficiency.

    Mechanism of Action

    Tretten consists of coagulation factor XIII A-subunit (recombinant). Recombinant human factor XIII (rFXIII) is integral in the formation of blood clots. In the absence of factor XIII, loosely formed clots are developed, leading to bleeding complications.

    Side Effects

    Adverse effects associated with the use of Tretten may include, but are not limited to, the following:

    • headache
    • pain in the extremities
    • injection site pain
    • D-dimer increase

    Dosing/Administration

    Tretten is supplied as a solution for infusion. The recommended dose is monthly 35 IU/kg injections.

    Clinical Trial Results

    The FDA approval of Tretten was based on a phase 3 trial in 41 subjects. Data showed that when compared to an historic control group of subjects who did not receive routine FXIII infusions, preventive treatment with monthly 35 IU/kg Tretten injections significantly decreased the number of treatment-requiring bleeding episodes. During the prophylaxis treatment period with Tretten (434 subject months), five bleeding episodes treated with FXIII-containing products were observed in four subjects. All five were associated with trauma. When calculated for all 41 subjects, this translated into a mean annual rate of bleeding episodes that required treatment of 0.14 per subject year, which was statistically significantly lower than the historic bleeding rate of 1.68 per subject year for on-demand treatment.

    Company Name: Novo Nordisk
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing